In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...

ACADIA Pharmaceuticals Inc (ACAD) reports an 18% increase in net sales and outlines promising growth strategies amidst challenges in product penetration and patient adherence.

Analyst Joel Beatty of Robert W. Baird maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of ...

We recently compiled a list of the 10 Worst-Performing Growth Stocks in 2024. In this article, we are going to take a look at ...

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

Acadia Pharmaceuticals ACAD reported third-quarter 2024 earnings of 20 cents per share, beating the Zacks Consensus Estimate ...

On Monday, ACADIA Pharmaceuticals Inc (ACAD) stock saw a decline, ending the day at $14.62 which represents a decrease of $-0.19 or -1.28% from the prior close of $14.81. The stock opened at $14.73 ...

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Camp Hill field hockey bounced back after losing to Boiling Springs in the semifinals of the District 3 1A tournament. • Sign ...

When healthcare providers devalue the pain of marginalized people, it results in inadequate and sometimes life-threatening ...